Literature DB >> 13189056

The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid.

W S SCHWARTZ, R E MOYER.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; NICOTINIC ACID/derivatives; PARA-AMINOSALICYLIC ACID/therapeutic use; STREPTOMYCIN/therapeutic use; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1954        PMID： 13189056     DOI： 10.1164/art.1954.70.3.413

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  5 in total

1.  Hyperuricaemia due to pyrazinamide.

Authors:  J SCHNEEWEISS; G W POOLE
Journal:  Br Med J       Date:  1960-09-17

2.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

4.  [Probable genetic loading of the population with "INH" (Isonicotinic hydrazide) (author's transl)].

Authors:  H Schmidt
Journal:  Humangenetik       Date:  1973

5.  Optimising pyrazinamide for the treatment of tuberculosis.

Authors:  Nan Zhang; Radojka M Savic; Martin J Boeree; Charles A Peloquin; Marc Weiner; Norbert Heinrich; Erin Bliven-Sizemore; Patrick P J Phillips; Michael Hoelscher; William Whitworth; Glenn Morlock; James Posey; Jason E Stout; William Mac Kenzie; Robert Aarnoutse; Kelly E Dooley
Journal:  Eur Respir J       Date:  2021-07-20       Impact factor: 33.795
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.